Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 5/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | SDCBP | O00560 | 1/20 | 0.38 |
| ▸ | SDC2 | P34741 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875732 | 0.89 | CA2 (0.49) | CA2CA1MMP1MMP3MMP9 | |
| SCHEMBL2875736 | 0.89 | CA2 (0.49) | CA2CA1MMP1MMP3MMP9 | |
| SCHEMBL1912126 | 0.84 | CA2 (0.51) | CA2CA1MMP1MMP3MMP9 | |
| SCHEMBL10286652 | 0.80 | SDCBP (0.49) | CTSKCTSSSDCBPSDC2 | |
| SCHEMBL13654766 | 0.78 | CA2 (0.43) | CA2CA1MMP1MMP3MMP9 | |
| SCHEMBL402017 | 0.77 | CA2 (0.46) | CA2CA1CTSKCTSS | |
| SCHEMBL5128800 | 0.77 | HDAC6 (0.42) | CA2CA1 | |
| SCHEMBL402433 | 0.76 | CA2 (0.40) | CA2CA1MMP1MMP3MMP9 | |
| SCHEMBL402432 | 0.76 | CA2 (0.40) | CA2CA1MMP1MMP3MMP9 | |
| SCHEMBL2260206 | 0.75 | CA1 (0.54) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CA2 3457/4885CA1 4246/4885MMP1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.